8-K: Ligand Pharmaceuticals Invests $50 Million in Castle Creek Biosciences to Advance Gene Therapy for Dystrophic Epidermolysis Bullosa

Ligand Pharmaceuticals leads a $75 million royalty financing round for Castle Creek Biosciences to support the Phase 3 clinical trial of D-Fi, a gene therapy for dystrophic epidermolysis bullosa (DEB).

Summary

• Ligand Pharmaceuticals has invested $50 million in Castle Creek Biosciences to support the Phase 3 clinical study of D-Fi, a gene therapy for dystrophic epidermolysis bullosa (DEB).
• A syndicate of co-investors contributed an additional $25 million, bringing the total investment to $75 million.
• In return for the investment, Ligand and the co-investors will receive a high single-digit royalty on worldwide sales of D-Fi.
• Ligand also acquired an unsecured subordinated promissory note from Castle Creek for $1.8 million, with a principal amount of $8.3 million, payable upon FDA approval of D-Fi.
• Ligand obtained warrants to purchase shares of Castle Creek Biosciences, Inc. Series D-1 Preferred Stock, exercisable until February 24, 2035.
• Castle Creek granted the Purchasers a security interest in certain assets related to the programs included in the Agreement.

Sentiment

Score: 7

Explanation: The sentiment is positive due to Ligand's strategic investment in a promising gene therapy, the potential for future royalty revenue, and the FDA designations already granted to D-Fi. However, the forward-looking statements and associated risks temper the overall sentiment.

Positives

• Ligand's investment supports the development of a potential treatment for a rare and debilitating genetic skin disorder.
• The royalty financing agreement provides Ligand with a potential revenue stream from future sales of D-Fi.
• D-Fi has already received multiple designations from the FDA, which could expedite its approval process.
• The investment diversifies Ligand's portfolio of revenue-generating assets.
• The syndicate includes existing Castle Creek investors Paragon Biosciences and Valor Equity Partners and new investor XOMA Royalty Corporation (Nasdaq: XOMA).

Negatives

• The success of D-Fi is dependent on the outcome of the Phase 3 clinical trial and regulatory approval.
• Ligand may not receive the expected revenue under the agreement if D-Fi fails to gain regulatory approval or achieve commercial success.
• There are risks associated with protecting intellectual property related to D-Fi.
• The promissory note is unsecured and subordinated, increasing the risk of non-payment.

Risks

• Failure to meet expectations regarding the Phase 3 trial of D-Fi could negatively affect Ligand's financial condition and stock price.
• Ligand's partners may not be able to protect their intellectual property, potentially exposing Ligand to liabilities.
• Patents covering certain products and technologies may be challenged or invalidated.
• The forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

Future Outlook

Ligand anticipates potential revenue from royalty payments based on the success of D-Fi's Phase 3 trial and subsequent commercialization. The company acknowledges risks related to clinical trial outcomes, regulatory approvals, and intellectual property protection.

Management Comments

• Todd Davis, CEO of Ligand, stated that the collaboration reflects their commitment to invest in groundbreaking de-risked treatments that can transform patients' lives and expand their diversified portfolio of revenue-generating assets.
• Matthew Gantz, president and CEO of Castle Creek, commented that Ligand and the syndicate of investors recognized the potential of this critical therapy and that the transaction will support their Phase 3 clinical trial.

Industry Context

This announcement reflects a growing trend in the biopharmaceutical industry of companies investing in and partnering with smaller firms to develop innovative therapies, particularly in the orphan drug space. Royalty financing is a common mechanism for funding late-stage clinical trials, allowing investors to share in the potential upside of successful drug development.

Comparison to Industry Standards

• Royalty financing deals in the biopharmaceutical industry typically involve a range of royalty rates, often in the single to low double-digit range, depending on the stage of development, market potential, and associated risks.
• Similar deals include XOMA's royalty interest acquisitions, which often focus on late-stage or commercialized products to generate immediate revenue.
• Ligand's diversified business model, which includes royalty streams, technology licensing, and internal drug development, is comparable to companies like Royalty Pharma, which specializes in acquiring royalty interests in pharmaceutical products.

Stakeholder Impact

• Shareholders of Ligand may benefit from potential future royalty revenues if D-Fi is successful.
• Patients with DEB could benefit from a new and effective treatment option.
• Castle Creek Biosciences receives funding to advance its lead candidate through clinical development.

Next Steps

• Castle Creek will continue the Phase 3 clinical trial of D-Fi for patients with DEB.
• Ligand will file the full Purchase and Sale Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.
• Ligand will monitor the progress of D-Fi's clinical development and regulatory pathway.

Key Dates